Abstract
The inhibitory protein SOCS3 plays a key part in the immune and hematopoietic systems by regulating signaling induced by specific cytokines. SOCS3 functions by inhibiting the catalytic activity of Janus kinases (JAKs) that initiate signaling within the cell. We determined the crystal structure of a ternary complex between mouse SOCS3, JAK2 (kinase domain) and a fragment of the interleukin-6 receptor β-chain. The structure shows that SOCS3 binds JAK2 and receptor simultaneously, using two opposing surfaces. While the phosphotyrosine-binding groove on the SOCS3 SH2 domain is occupied by receptor, JAK2 binds in a phosphoindependent manner to a noncanonical surface. The kinase-inhibitory region of SOCS3 occludes the substrate-binding groove on JAK2, and biochemical studies show that it blocks substrate association. These studies reveal that SOCS3 targets specific JAK–cytokine receptor pairs and explains the mechanism and specificity of SOCS action.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wilks, A.F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86, 1603–1607 (1989).
Wilks, A.F. & Oates, A.C. The JAK/STAT pathway. Cancer Surv. 27, 139–163 (1996).
Shuai, K. et al. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 366, 580–583 (1993).
Darnell, J.E. Jr., Kerr, I.M. & Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415–1421 (1994).
Endo, T.A. et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921–924 (1997).
Hilton, D.J. et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA 95, 114–119 (1998).
Naka, T. et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924–929 (1997).
Starr, R. et al. A family of cytokine-inducible inhibitors of signalling. Nature 387, 917–921 (1997).
Babon, J.J. et al. The SOCS box domain of SOCS3: Structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J. Mol. Biol. 381, 928–940 (2008).
Babon, J.J., Sabo, J.K., Zhang, J.G., Nicola, N.A. & Norton, R.S. The SOCS box encodes a hierarchy of affinities for cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression. J. Mol. Biol. 387, 162–174 (2009).
Kamizono, S. et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276, 12530–12538 (2001).
Zhang, J.G. et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96, 2071–2076 (1999).
Zhang, J.G. et al. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. USA 98, 13261–13265 (2001).
Sasaki, A. et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4, 339–351 (1999).
Yasukawa, H. et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309–1320 (1999).
Boyle, K. et al. Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell Signal. 21, 394–404 (2009).
Babon, J.J. et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239–250 (2012).
Roberts, A.W. et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. USA 98, 9324–9329 (2001).
Yasukawa, H. et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4, 551–556 (2003).
Croker, B.A. et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20, 153–165 (2004).
Mori, H. et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat. Med. 10, 739–743 (2004).
Hörtner, M. et al. Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J. Immunol. 169, 1219–1227 (2002).
De Souza, D. et al. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41, 9229–9236 (2002).
Nicholson, S.E. et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA 97, 6493–6498 (2000).
Skiniotis, G., Lupardus, P.J., Martick, M., Walz, T. & Garcia, K.C. Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. Mol. Cell 31, 737–748 (2008).
Bergamin, E., Wu, J. & Hubbard, S.R. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure 14, 1285–1292 (2006).
Lucet, I.S. et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176–183 (2006).
Knighton, D.R. et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407–414 (1991).
Babon, J.J. et al. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol. Cell 22, 205–216 (2006).
Babon, J.J. et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239–250 (2012).
Hubbard, S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572–5581 (1997).
Nicholson, S.E. et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18, 375–385 (1999).
Blat, Y. Non-competitive inhibition by active site binders. Chem. Biol. Drug Des. 75, 535–540 (2010).
Yoshimura, A. The CIS family: negative regulators of JAK-STAT signaling. Cytokine Growth Factor Rev. 9, 197–204 (1998).
Moncoq, K. et al. The PIR domain of Grb14 is an intrinsically unstructured protein: implication in insulin signaling. FEBS Lett. 554, 240–246 (2003).
Depetris, R.S. et al. Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Mol. Cell 20, 325–333 (2005).
Béréziat, V. et al. Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14. J. Biol. Chem. 277, 4845–4852 (2002).
Lei, M. et al. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 102, 387–397 (2000).
James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).
Chen, E., Staudt, L.M. & Green, A.R. Janus kinase deregulation in leukemia and lymphoma. Immunity 36, 529–541 (2012).
Tefferi, A. & Pardanani, A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 25, 229–237 (2011).
Karplus, P.A. & Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030–1033 (2012).
Babon, J.J. et al. Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. FEBS J. 272, 6120–6130 (2005).
Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D Biol. Crystallogr. 66, 133–144 (2010).
McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).
Griffin, M.D. et al. Characterisation of the first enzymes committed to lysine biosynthesis in Arabidopsis thaliana. PLoS ONE 7, e40318 (2012).
Petoukhov, M.V., Konarev, P.V., Kikhney, A.G. & Svergun, D.I. ATSAS 2.1—towards automated and web-supported small-angle scattering data analysis. J. Appl. Crystallogr. 40, S223–S228 (2007).
Konarev, P.V., Volkov, V.V., Sokolova, A.V., Koch, M.H.J. & Svergun, D.I. PRIMUS: a Windows PC-based system for small-angle scattering data analysis. J. Appl. Crystallogr. 36, 1277–1282 (2003).
Svergun, D.I. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Crystallogr. 25, 495–503 (1992).
Svergun, D., Barberato, C. & Koch, M.H.J. CRYSOL—a program to evaluate x-ray solution scattering of biological macromolecules from atomic coordinates. J. Appl. Crystallogr. 28, 768–773 (1995).
Franke, D. & Svergun, D.I. DAMMIF, a program for rapid ab-initio shape determination in small-angle scattering. J. Appl. Crystallogr. 42, 342–346 (2009).
Volkov, V.V. & Svergun, D.I. Uniqueness of ab initio shape determination in small-angle scattering. J. Appl. Crystallogr. 36, 860–864 (2003).
Kozin, M.B. & Svergun, D.I. Automated matching of high- and low-resolution structural models. J. Appl. Crystallogr. 34, 33–41 (2001).
Acknowledgements
We thank P. Colman, P. Czabotar and M. Lawrence for advice and I. Segel for helpful discussions. This work was supported in part by the National Health and Medical Research Council of Australia (NHMRC), program grants 461219 and 1016647 (N.A.N.) and project grant 1011804 (J.J.B.), the US National Institutes of Health CA22556 (N.A.N.), the Victorian State Government Operational Infrastructure Support grant and the NHMRC Independent Research Institutes Infrastructure Support Scheme (361646). N.A.N. acknowledges fellowship support from the NHMRC, J.M.M. and J.J.B. from the Australian Research Council and L.N.V. from the Leukaemia Foundation of Australia and the Australian Stem Cell Centre. We thank the scientists at the MX and SAXS/WAXS beamlines at the Australian Synchrotron. Crystallization trials were performed at CSIRO collaborative crystallization centre (C3).
Author information
Authors and Affiliations
Contributions
N.J.K. carried out crystallographic data collection, structure determination and refinement. J.J.B. and N.P.D.L. performed inhibition and co-precipitation assays. J.M.M. and L.N.V. carried out SAXS data collection and analysis. J.M.M., A.L., I.S.L. and E.L.W. performed protein expression and purification experiments. All authors commented on the manuscript . J.J.B., N.J.K. and N.A.N. designed experiments, analyzed data, supervised the project and wrote the paper.
Corresponding authors
Ethics declarations
Competing interests
N.A.N. is a founder and member of the scientific advisory board of MuriGen Pty Ltd.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–7, Supplementary Table 1 and Supplementary Note (PDF 1516 kb)
Rights and permissions
About this article
Cite this article
Kershaw, N., Murphy, J., Liau, N. et al. SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 20, 469–476 (2013). https://doi.org/10.1038/nsmb.2519
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nsmb.2519
This article is cited by
-
Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship
Molecular Diversity (2024)
-
Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy
Cell Communication and Signaling (2023)
-
Recent advances in anti-inflammatory active components and action mechanisms of natural medicines
Inflammopharmacology (2023)
-
miR-181a is a novel player in the STAT3-mediated survival network of TCRαβ+ CD8+ T large granular lymphocyte leukemia
Leukemia (2022)
-
Leukaemia inhibitory factor in gastric cancer: friend or foe?
Gastric Cancer (2022)